The CMV Resistance Puzzle

The best time of the week has arrived—I genuinely look forward to sitting down to write these posts. It gives me a moment to reflect on infectious disease topics I’m deeply passionate about.

Today, I want to touch on the management of cytomegalovirus (CMV) resistance mutations, a topic I encountered recently in clinical practice. This post will be a short primer—there’s a lot more to explore in the world of CMV, and I plan to dive deeper in future posts.

Let’s start by reviewing the mechanisms of action of the antivirals currently available for CMV treatment, and the resistance mutations that can limit their effectiveness.

Two caveats upfront:

• Letermovir won’t be discussed here, as it's used primarily for prophylaxis, not treatment. That will be a topic for another time.

• CMV resistance testing is usually genotypic, not phenotypic (just for research purposes). So results should be interpreted cautiously—they estimate the likelihood of resistance based on codon changes and correlate with data from limited phenotypic studies.

CMV Antiviral Targets: Polymerase vs Kinase

CMV antivirals generally fall into two categories based on their targets:

1. CMV DNA polymerase inhibitors (target: UL54 gene)

2. Viral protein kinase inhibitors (target: UL97 gene)

Let’s break them down.

1. Polymerase Inhibitors

A. Ganciclovir / Valganciclovir

These are the most commonly used agents. They require phosphorylation by the UL97 viral kinase to become active, and then inhibit viral DNA polymerase (UL54).

• Resistance mechanisms:

  • UL97 mutations → reduced phosphorylation → high-level resistance to ganciclovir

  • UL54 mutations (less common) → direct resistance to polymerase inhibition

B. Cidofovir

Cidofovir does not require phosphorylation by UL97 and inhibits the DNA polymerase directly after minimal phosphorylation by other intracellular kinases.

• Resistance mechanism:

  • UL54 mutations → cidofovir resistance

C. Foscarnet

Foscarnet does not require any phosphorylation and binds directly to the viral DNA polymerase.

• Resistance mechanism:

  • UL54 mutations → but usually at different codons than cidofovir, so cross-resistance is variable

2. UL97 Kinase Inhibitor: Maribavir

Maribavir is a selective inhibitor of the UL97 protein kinase. It doesn’t need intracellular phosphorylation and interferes with phosphorylation of viral proteins essential for replication and nuclear egress.

• Interesting point: Because UL97 is needed to activate ganciclovir, maribavir and ganciclovir are antagonistic.

• However, resistance to maribavir typically means UL97 is still functional—so the virus may remain susceptible to ganciclovir!

• Maribavir does not affect cidofovir or foscarnet activity, since those don’t rely on UL97 phosphorylation.

Summary

When evaluating CMV resistance, it’s essential to understand the antiviral targets and corresponding resistance mechanisms:

• Ganciclovir/Valganciclovir → resistance via UL97 and UL54 mutations or both

• Cidofovir/Foscarnet → resistance via UL54 mutations

• Maribavir → targets UL97; resistance here may restore ganciclovir susceptibility

Each case of CMV resistance requires a tailored approach, factoring in drug toxicity, routes of administration, and the resistance profile.

I hope this breakdown was helpful (and not too confusing!). In the coming weeks, I’ll cover when to treat CMV, medication side effects, and other practical pearls I’ve found useful in real-world care.

Until next time!

🎵 Musical Coda

When I think about viral replication and mutations: